187 related articles for article (PubMed ID: 21606417)
1. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer.
Yang M; Xie W; Mostaghel E; Nakabayashi M; Werner L; Sun T; Pomerantz M; Freedman M; Ross R; Regan M; Sharifi N; Figg WD; Balk S; Brown M; Taplin ME; Oh WK; Lee GS; Kantoff PW
J Clin Oncol; 2011 Jun; 29(18):2565-73. PubMed ID: 21606417
[TBL] [Abstract][Full Text] [Related]
2. SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.
Rajanala SH; Plym A; Vaselkiv JB; Ebot EM; Matsoukas K; Lin Z; Chakraborty G; Markt SC; Penney KL; Lee GM; Mucci LA; Kantoff PW; Stopsack KH
Carcinogenesis; 2024 Feb; 45(1-2):35-44. PubMed ID: 37856781
[TBL] [Abstract][Full Text] [Related]
3. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx.
Sissung TM; Ley AM; Strope JD; McCrea EM; Beedie S; Peer CJ; Shukla S; van Velkinburgh J; Reece K; Troutman S; Campbell T; Fernandez E; Huang P; Smith J; Thakkar N; Venzon DJ; Brenner S; Lee W; Merino M; Luo J; Jager W; Price DK; Chau CH; Figg WD
Mol Cancer Res; 2017 Aug; 15(8):1096-1105. PubMed ID: 28389619
[TBL] [Abstract][Full Text] [Related]
4. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
5. Concept and viability of androgen annihilation for advanced prostate cancer.
Mohler JL
Cancer; 2014 Sep; 120(17):2628-37. PubMed ID: 24771515
[TBL] [Abstract][Full Text] [Related]
6. Androgen Deprivation Therapy Unrelated to Alzheimer's Disease in the UK Biobank Cohort.
Lehrer S; Rheinstein PH
Anticancer Res; 2023 Jan; 43(1):437-440. PubMed ID: 36585167
[TBL] [Abstract][Full Text] [Related]
7. Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia.
Kiyotani K; Mushiroda T; Kubo M; Zembutsu H; Sugiyama Y; Nakamura Y
Cancer Sci; 2008 May; 99(5):967-72. PubMed ID: 18294295
[TBL] [Abstract][Full Text] [Related]
8. Deep reinforcement learning identifies personalized intermittent androgen deprivation therapy for prostate cancer.
Lu Y; Chu Q; Li Z; Wang M; Gatenby R; Zhang Q
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38493345
[TBL] [Abstract][Full Text] [Related]
9. Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.
Chen JY; Chang CF; Huang SP; Huang CY; Yu CC; Lin VC; Geng JH; Li CY; Lu TL; Bao BY
BMC Med Genomics; 2024 Jan; 17(1):41. PubMed ID: 38287309
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation.
Fujimoto N; Kubo T; Inatomi H; Bui HT; Shiota M; Sho T; Matsumoto T
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):336-40. PubMed ID: 23896625
[TBL] [Abstract][Full Text] [Related]
11. SLCO1B1, SLCO2B1, and SLCO1B3 polymorphisms and susceptibility to bladder cancer risk.
Bui HT; Fujimoto N; Kubo T; Inatomi H; Matsumoto T
Cancer Invest; 2014 Jul; 32(6):256-61. PubMed ID: 24762081
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
Jabir RS; Naidu R; Annuar MA; Ho GF; Munisamy M; Stanslas J
Pharmacogenomics; 2012 Dec; 13(16):1979-88. PubMed ID: 23215890
[TBL] [Abstract][Full Text] [Related]
13. Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.
Choi JR; Kim JO; Kang DR; Shin JY; Zhang XH; Oh JE; Park JY; Kim KA; Kang JH
Cancer Res Treat; 2015 Jul; 47(3):509-17. PubMed ID: 25648089
[TBL] [Abstract][Full Text] [Related]
14. Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Bedewy AM; El-Maghraby SM
Hematology; 2013 Jul; 18(4):211-6. PubMed ID: 23394475
[TBL] [Abstract][Full Text] [Related]
15. Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
Wang X; Harshman LC; Xie W; Nakabayashi M; Qu F; Pomerantz MM; Lee GS; Kantoff PW
J Clin Oncol; 2016 Feb; 34(4):352-9. PubMed ID: 26668348
[TBL] [Abstract][Full Text] [Related]
16. Association of Tissue Abiraterone Levels and
Mostaghel EA; Cho E; Zhang A; Alyamani M; Kaipainen A; Green S; Marck BT; Sharifi N; Wright JL; Gulati R; True LD; Loda M; Matsumoto AM; Tamae D; Penning TN; Balk SP; Kantoff PW; Nelson PS; Taplin ME; Montgomery RB
Clin Cancer Res; 2017 Aug; 23(16):4592-4601. PubMed ID: 28389510
[No Abstract] [Full Text] [Related]
17. Germline Variant in
Hahn AW; Gill DM; Poole A; Nussenzveig RH; Wilson S; Farnham JM; Stephenson RA; Cannon-Albright LA; Maughan BL; Agarwal N
Mol Cancer Ther; 2019 Mar; 18(3):726-729. PubMed ID: 30587554
[TBL] [Abstract][Full Text] [Related]
18. Role of hypoxia inducible factor-1α in the regulation of the cancer-specific variant of organic anion transporting polypeptide 1B3 (OATP1B3), in colon and pancreatic cancer.
Han S; Kim K; Thakkar N; Kim D; Lee W
Biochem Pharmacol; 2013 Sep; 86(6):816-23. PubMed ID: 23924606
[TBL] [Abstract][Full Text] [Related]
19. Detection of Extracellular Vesicle-Derived RNA as Potential Prostate Cancer Biomarkers: Role of Cancer-type SLCO1B3 and ABCC3.
Lee KY; Beatson EL; Knechel MA; Sommer ER; Napoli GC; Risdon EN; Leon AF; Depaz RD; Strope JD; Price DK; Chau CH; Figg WD
J Cancer; 2024; 15(3):615-622. PubMed ID: 38213719
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
